Seer markets its products for research use only to academic institutions, life sciences and research laboratories, and biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company has validated its Proteograph product suite for population-scale, peptide-level mass spectrometry proteomics through a Nature Genetics study, strengthening its competitive positioning in the emerging proteomics space.
Cyborg Score Rationale
Q3 2025 revenue was $4.1 million (up 2% YoY) with 51% gross margin, but operating expenses were $21.5 million with a net loss of $18.2 million. The company maintains strong cash position of $251.2 million, providing runway for growth, though early-stage revenue growth remains challenged.
Top Insights
Nearly three times more instrument shipments year-to-date vs. 2024 and a record >60 third-party publications indicate growing adoption and validation
Full-year 2025 revenue guidance of $17–$18 million represents midpoint +24% growth vs. 2024
Still operating exclusively in research-use-only market; diagnostic/clinical applications remain future opportunity
Global operations in China, Australia, Eastern Europe, Israel, Japan and South Africa provide geographic diversification
Named Competitors
Mass Spectrometry Platforms — Broad life sciences instrument portfolio including proteomics capabilities
Proteomics Platforms — Analytical instrument manufacturer with chromatography and mass spectrometry solutions
Emerging Proteomics Competitors — Alternative proteomics platform using different technology approaches
Recent Developments
(Feb 2026) Q4 2025 financial results reported
(Nov 2025) Nature Genetics publication validating Proteograph for population-scale proteomics
(Nov 2025) Q3 2025 results: $4.1M revenue, 51% gross margin, $18.2M net loss
Open the full interactive Seer Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.